AI
AVIR icon

Atom Investors’s Atea Pharmaceuticals AVIR Stock Holding History

Atom Investors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-30,911
Closed -$219K – 288
2022
Q2 		$219K Buy
+30,911
New +$211K 0.1% 178

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Atom Investors's AVIR Position: Q3 2022 in Review

Atom Investors sold out of Atea Pharmaceuticals (AVIR) in Q3 2022, closing a stake of 30,911 shares — an estimated $219K sold.

Atom Investors first reported a position in AVIR in Q2 2022 and held it in 1 quarter. The position peaked at $219K in Q2 2022. 126 funds tracked by Wall St. Rank hold AVIR as of Q3 2022.

  • Atom Investors reported no remaining Atea Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Atom Investors sold 30,911 Atea Pharmaceuticals shares in Q3 2022, an estimated $219K.
  • Atom Investors first reported a position in Atea Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Atom Investors's Atea Pharmaceuticals position peaked at $219K in Q2 2022.
  • 126 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2022.

Based on Atom Investors's 13F filing for Q3 2022, filed 8 Nov 2022.